Day: November 9, 2023

SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) —  Sonder Holdings Inc. (NASDAQ: SOND), a leading next-generation hospitality company that is redefining the guest experience through technology and design, today announced that it will report third quarter 2023 financial results on Tuesday, November 14, 2023. Sonder will share a brief advisory containing a link to the third quarter 2023 Shareholder Letter, available on the Company’s website. Management will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, following the release of its earnings materials, to discuss the Company’s financial and business results and outlook. What: Sonder Holdings Inc. Third Quarter 2023 CallWhen: Tuesday, November 14, 2023Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern TimeShareholder Letter: investors.sonder.com...

Third quarter revenue grew 24% year-over-year Forian data factory expanded to drive improved insights NEWTOWN, PA, Nov. 09, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended September 30, 2023. “Our strong financial quarter highlighted by an increase in Adjusted EBITDA is a testament to the hard work of the team and the scalability of our business model. We are committed to continuing to deliver valuable information products and intelligence to our customers. We continue to be prudent in cost containment while opportunistically investing in the business for long term organic growth,” stated Max Wygod, Chairman and Chief Executive Officer of Forian. Third...

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. “Our newly appointed Chief Medical Officer, Dr. Thomas Strack, who has been working with us on a consulting basis for several months, is now leading our work on the cadisegliatin Phase 3 program with the goal of initiating studies as soon as possible,” said Paul Sekhri, Chief Executive Officer of vTv. “Additionally, our partnered programs including azeliragon, licensed to Cantex Pharmaceuticals and mavodelpar, licensed...

Steady Year-over-Year Recurring Revenue Growth & Margin Expansion at Analytics; Free Cash Flow Generation Begins To Inflect TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) — Altus Group Limited (ʺAltus” or “the Company”) (TSX: AIF), a leading provider of asset and fund intelligence for commercial real estate (“CRE”), announced today its financial and operating results for the third quarter ended September 30th, 2023 and the approval by its Board of Directors of the payment of a cash dividend of $0.15 per common share for the fourth quarter ending December 31, 2023. Q3 2023 Summary: Unless otherwise indicated, all amounts are in Canadian dollars and percentages are on an as reported basis in comparison to Q3 2022.Consolidated revenues were $185.2 million, up 4.2% (0.8% on a Constant Currency* basis) Profit was $0.9 million, compared...

Rapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expansion nearly two quarters earlier than expected and enrolled first patient in Population Extension cohort Interim data update from 4D-150 PRISM Phase 2 Dose Expansion (n=50; high anti-VEGF need patients) in wet AMD expected in early 2024; update on FDA feedback on Phase 3 pivotal trial plans expected in Q1 2024 Received European Medicines Agency’s Priority Medicines (PRIME) designation for 4D-150 for treatment of wet AMD Announced positive interim data from 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis; update on FDA interaction expected in Q1 2024 Gained alignment with FDA on plan to lift clinical hold on 4D-310 for Fabry disease cardiomyopathy; interim Phase 1/2 data update expected in Q1...

BEDFORD, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) — Legacy Housing Corporation (“Legacy” or the “Company,” NASDAQ: LEGH) today announced its financial results for the third quarter ended September 30, 2023. Financial HighlightsNet revenue for the third quarter of 2023 was $49.9 million, a decrease of 12.9% from the third quarter of 2022. Income from operations for the third quarter of 2023 was $19.0 million, an increase of 12.8% from the third quarter of 2022. Net income for the third quarter of 2023 was $16.1 million, an increase of 9.2% from the third quarter of 2022. Basic earnings per share for the third quarter of 2023 was $0.66, an increase of 10.0% from the third quarter of 2022. Book value for the third quarter of 2023 was $429.5 million, an increase of 18.6% from the third quarter of 2022. Book value per share for...

Record quarterly revenue of $7.1 million represents an increase of 41.5% year-over-year and seventh consecutive quarter of sequential revenue growth PLEASANTON, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) — ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the leading non-CPAP Obstructive Sleep Apnea Therapy, today announced financial results for the third quarter ended September 30, 2023. Recent Business HighlightsGenerated record revenues of $7.1 million in the quarter, representing an increase of 41.5% year-over-year compared to the third quarter of 2022, and $19.8 million for the nine months ended 2023, representing a 45.7% increase compared to 2022. Completed a $10.4 million financing during the third quarter, the net proceeds from which will fund operations as the company works to achieve cash flow breakeven. Reduced operating...

CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent and upcoming business highlights. “During the third quarter of this year, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 (“CLDN6”) x CD3 bispecific antibody, toward a first-in-human clinical study. Preclinical data presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting showed...

Third Quarter Financial Results(in thousands) Q3 23 Q3 22 YOYChange  Q3 23 YTD Q3 22 YTD YOYChange Total Revenues $ 4,472 $ 4,442 0.7 % $ 13,449 $ 13,689 (1.8 %)Operating Income 467 671 (30.4 %) 845 2,585 (67.3 %)Income Before Provision for Taxes 485 776 (37.5 %) 783 2,789 (71.9 %)Net Income 359 1,887 (81.0 %) 504 3,547 (85.8 %)Gross Billings* 16,158 16,264 (0.7 %) 51,286 50,513 1.5 %EBITDA* 540 820 (34.1 %) 946 2,944 (67.9 %)Adjusted EBITDA* 547 768 (28.8 % 1,081 2,898 (62.7 %)Pre-Corporate EBITDA* 795 1,015 (21.7 %) 1,819 3,621 (49.8 %)*Non-GAAP measures referenced are detailed in the disclosures at the end of this release.         DALLAS, Nov. 09, 2023 (GLOBE NEWSWIRE) — Wilhelmina International, Inc. (Nasdaq:WHLM) (“Wilhelmina” or the “Company”) today reported revenues...

OLD GREENWICH, Conn., Nov. 09, 2023 (GLOBE NEWSWIRE) — Hudson Global, Inc. (Nasdaq: HSON) (“Hudson Global” or “the Company”), a leading global total talent solutions company, announced today financial results for the third quarter ended September 30, 2023. 2023 Third Quarter SummaryRevenue of $39.4 million decreased 19.1% from the third quarter of 2022 and 17.9% in constant currency. Adjusted net revenue of $19.4 million decreased 20.0% from the third quarter of 2022 and 19.9% in constant currency. Net income was $0.5 million, or $0.17 per diluted share, compared to net income of $1.0 million, or $0.30 per diluted share, for the third quarter of 2022. Adjusted net income per diluted share (non-GAAP measure)* was $0.24 compared to adjusted net income per diluted share of $0.58 in the third quarter of 2022. Adjusted...